393108-57-1

Basic information

• Product Name: Aliskiren InterMediates
• Synonyms: (2S,4S,5S,7S)-5-(tert-butoxycarbonylaMino)-4-hydroxy-2-isopropyl-7-(4-Methoxy-3-(3-Methoxypropoxy)benzyl)-8-Methylnonanoic acid;Aliskiren InterMediates;(3S,5S)-3-isopropyl-5-((2S,4S)-4-isopropyl-5-oxo-tetrahydro-furan-2-yl)pyrrolidin-2-one;(3S,5S)-tert-butyl 3-isopropyl-5-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylate;(3S,5S)-5-[(1R,3S)-1-Bromo-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]dihydro-3-isopropyl-2(3H)-furanone;Aliskiren I
• CAS NO: 393108-57-1
• Molecular Formula: C25H39BrO5
• Molecular Weight: 499.47816
• Mol File: 393108-57-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.175
• CAS DataBase Reference: Aliskiren InterMediates(CAS DataBase Reference)
• NIST Chemistry Reference: Aliskiren InterMediates(393108-57-1)
• EPA Substance Registry System: Aliskiren InterMediates(393108-57-1)

Safety Data

• Hazardous Substances Data: 393108-57-1(Hazardous Substances Data)

Usage

General Description

Aliskiren Intermediates are a group of chemical compounds that are used in the production and synthesis of aliskiren, a medication used for the treatment of high blood pressure. These intermediates play a crucial role in the manufacturing process of aliskiren, as they are used as starting materials or key building blocks for the synthesis of the active pharmaceutical ingredient. Some of the common aliskiren intermediates include (2S,4aS,6aS,7aS)-octahydro-1H-indole hydrochloride, (2S,4aS,6aS,7aS)-1-(2-((((5-(2-methoxyphenoxy)pyrimidin-4-yl)oxy)methyl)tetrahydrofuro[3,4-d][1,3]dioxol-6-yl)oxy)octahydro-1H-indole, and (2S,4aS,6aS,7aS)-octahydro-1H-indole. These intermediates are essential for the pharmaceutical industry, as they enable the large-scale production of aliskiren for use in clinical settings.

Upstream product

• 172900-70-8 (R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutanol 
• 324763-39-5 (R)-2-[4-methoxy-3-(3-methoxypropoxyl)]phenylmethyl-3-methyl-1-chlorobutane 
• 324519-68-8 trans-(2S)-5-chloro-2-isopropyl-N,N-dimethyl-4-pentenamide 
• 503-74-2 3-methylbutyric acid 
• 172900-71-9 (R)-3-[4-methoxy-3-(3-methoxypropoxy)phenyl]-2-(1-methylethyl)propanoic acid 
• 172900-73-1 4-(bromomethyl)-1-methoxy-2-(3-methoxypropoxy)-benzene 
• 172900-74-2 [4-methoxy-3-(3-methoxypropoxy)-phenyl]methanol 
• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 324519-67-7 (S,E)-ethyl 5-chloro-2-isopropylpent-4-enoate 
• 387353-77-7 methyl (S)-(4E)-5-chloro-2-isopropyl-4-pentenoate 
• 325154-26-5 (2S,7R,E)-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-N,N,8-trimethylnon-4-enamide 
• 387353-70-0 (2S,7R,E)-ethyl 2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnon-4-enoate 
• 387353-71-1 (2S,7R,E)-methyl 2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnon-4-enoate 
• 1350705-34-8 (S,E)-5-chloro-2-isopropylpent-4-enoic acid tert-butylamine 

Downstream Products

• 325154-32-3 (2S,4S,5R,7S)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-isopropylnonanamide 

Relevant articles and documents

A aliskiren or its salt separation and analysis method

The invention relates to a separation analysis method using polysaccharide derivative-bonded and coated silica as a stationary phase and an organic solvent as a mobile phase for separation analysis of aliskiren and isomers thereof, effective separation of the aliskiren and isomers thereof can be realized, and the separation analysis method has the important meaning to the product quality control.

A total synthesis of aliskiren

A total synthesis of aliskiren (20) was accomplished. A key in our synthesis was to use the symmetric trans-cisoid-trans-bis-lactone 1 as a precursor. It was expediently prepared by three different routes (Scheme 2). Appending the end groups and functional group transformations completed the synthesis (Scheme 3). Copyright

AMIDE INHIBITORS OF RENIN

The present invention relates to new amide inhibitors of renin, pharmaceutical compositions thereof, and methods of use thereof